



Nexstim releases the NBS 6 for diagnostic use in the United States

Press release, Helsinki, 10 October 2025 at 4 PM (EEST)

Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") announces the launch of the diagnostic applications of the NBS 6, a new navigated transcranial magnetic stimulation (nTMS) system software generation, in the United States.

The NBS 6 enables Nexstim's unique E-field navigated TMS technology to be used more easily than ever before. Part of this new product generation is an easy-to-use, software-guided application and a modular product design that allows for system capabilities to expand over time and be highly customized based on a customer's research or clinical interests.

Nexstim announced the release of the NBS 6 for therapy applications in 2023. Due to the modularity of the system, customers will now be able to order the NBS 6 with a combination of therapy and diagnostic modules.

The NBS 6 is FDA-cleared for pre-procedural mapping of the speech and motor cortices of the brain, and also indicated for the treatment of Major Depressive Disorder (MDD) in adult patients who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode.

More information on the NBS 6 system is available on Nexstim's website:

www.nexstim.com/healthcare-professionals/nbs-6.

The NBS 6 received MDR (Regulation (EU) 2017/745) certification in the European Union earlier in October 2025.

Mikko Karvinen, CEO of Nexstim, comments: *"Over the years we have noted the strong interest of our customers to have both diagnostic and therapeutic capabilities available in the same system. The idea behind the NBS 6 throughout the product development process has been to not only offer the best possible level of usability of our technology, but to build the system on modularity. This offers us interesting possibilities also when it comes to potential future releases of new indications."*

Since the release of the NBS 6 for therapy use, we have received lots of positive feedback on the system from customers. We also gained a positive reaction from long-time TMS users and interested attendees as we showcased the NBS 6 for pre-procedural mapping at the 13th International Symposium on nTMS in Neurosurgery and Neuromodulation in Berlin last fall. We are excited for our existing and new customers to get their hands on the system.

The release of the NBS 6 with diagnostic features to the US is a huge milestone achievement for Nexstim. I would like to give my biggest thanks to the Nexstim team for years of hard work, as well as to our valuable customers that have been involved in how the final product evolved."

Further information is available on the website www.nexstim.com, or by contacting:

Mikko Karvinen, CEO

+358 50 326 4101

mikko.karvinen@nexstim.com



About Nexstim Plc

Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.

Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.

Nexstim's Diagnostics Business focuses on commercialization of the NBS System 6, which is the only FDA-cleared and CE-marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.

Nexstim's Therapy Business markets and sells the NBS System 6 which is FDA-cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBS 6 system is CE-marked for the treatment of major depression and chronic neuropathic pain.

Nexstim shares are listed on Nasdaq First North Growth Market Finland.

For more information, please visit www.nexstim.com.